Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
Andreas Kindmark(AstraZeneca (Sweden)), A Jawaid(AstraZeneca (United Kingdom)), Chris Harbron(AstraZeneca (United Kingdom)), Bryan J. Barratt(AstraZeneca (United Kingdom)), Olof Bengtsson(AstraZeneca (Sweden)), Tommy B. Andersson(AstraZeneca (Sweden)), Stefan Carlsson(AstraZeneca (Sweden)), Karin Cederbrant(AstraZeneca (Sweden)), Neil Gibson(AstraZeneca (United Kingdom)), Melissa J. Armstrong(AstraZeneca (United Kingdom)), M E Lagerström-Fermér(AstraZeneca (Sweden)), Anita Dellsèn(AstraZeneca (Sweden)), Ellen M. Brown(AstraZeneca (United Kingdom)), Matthew E. Thornton(AstraZeneca (United Kingdom)), Cynthia Dukes(AstraZeneca (United Kingdom)), Suzanne Jenkins(AstraZeneca (United Kingdom)), Mike Firth(AstraZeneca (United Kingdom)), Grace Harrod(AstraZeneca (United Kingdom)), Tracy Pinel(AstraZeneca (United Kingdom)), S M E Billing-Clason(AstraZeneca (Sweden)), Lon R. Cardon(Centre for Human Genetics), Ruth March(AstraZeneca (United Kingdom))
Cited by 368
Abstract
Related Papers
No related papers found
Powered by citation graph analysis